Presence of normal olfactory function · participants with olfactory dysfunction following COVID‐19 for ≤ 15 days
Intranasal steroid drops showed no clear difference in presence of normal olfactory function Assessed by participants > 4… compared with placebo (low certainty).
1 finding from 1 review
Serious adverse effects · participants with olfactory dysfunction following COVID‐19 for ≤ 15 days
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in sense of smell · participants with olfactory dysfunction following COVID‐19 for ≤ 15 days
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Prevalence of parosmia · participants with olfactory dysfunction following COVID‐19 for ≤ 15 days
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in taste · participants with olfactory dysfunction following COVID‐19 for ≤ 15 days
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Disease‐related quality of life · participants with olfactory dysfunction following COVID‐19 for ≤ 15 days
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Other adverse effects · participants with olfactory dysfunction following COVID‐19 for ≤ 15 days
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Wait‐list compared with no‐treatment · patients with mental health disorders
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Non‐serious adverse events for all placebos compared with wait‐list or no treatment (Spontaneous reporting of dichotomous outcomes) (Post‐treatment) · patients with mental health disorders
It is very uncertain whether the intervention changes non‐serious adverse events for all placebos compared with wait‐list… (very low certainty).
1 finding from 1 review
Intervention not reported
Usual care compared with wait‐list/no‐treatment (Variety of continuous outcome) (Post‐treatment) · patients with mental health disorders
1 finding from 1 review
Intervention not reported
Serious adverse events for all placebos · patients with mental health disorders
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Non‐serious adverse events for all placebos · patients with mental health disorders
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
All placebos compared with wait‐list or no‐treatment (Variety of continuous outcome) (Post‐treatment) · patients with mental health disorders
1 finding from 1 review
Intervention not reported
Psychological placebos compared with wait‐list or no‐treatment (Variety of continuous outcome) (Post‐treatment) · patients with mental health disorders
1 finding from 1 review
Intervention not reported
Pharmacological placebos compared with wait‐list or no‐treatment (Variety of continuous outcome) (Post‐treatment) · patients with mental health disorders
1 finding from 1 review
Intervention not reported
Physical placebos compared with wait‐list or no‐treatment (Variety of continuous outcome) (Post‐treatment) · patients with mental health disorders
1 finding from 1 review
Intervention not reported
Serious adverse events for all placebos compared with wait‐list or no treatment (Spontaneous reporting of dichotomous outcomes) (Post‐treatment) · patients with mental health disorders
It is very uncertain whether the intervention changes serious adverse events for all placebos compared with wait‐list or… (very low certainty).
1 finding from 1 review
Presence of dry socket · Adults (>18 years) having permanent tooth extraction (predominantly mandibular third molars)
Herbal mouthrinse showed no clear difference in presence of dry socket compared with chlorhexidine 0.2% mouthrinse; GRADE not reported.
1 finding from 1 review
Presence of dry socket · Adults (>18 years) having permanent tooth extraction (predominantly mandibular third molars)
Acellular dermal matrix led to lower presence of dry socket compared with control; GRADE not reported.
1 finding from 1 review
Presence of dry socket · Adults (>18 years) having permanent tooth extraction (predominantly mandibular third molars)
It is very uncertain whether platelet rich plasma changes presence of dry socket compared with placebo or no treatment (very low certainty).
1 finding from 1 review